Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31585948 | 1.00 | MAPT (0.43) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL31586047 | 0.87 | MAPT (0.40) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL31585889 | 0.86 | RORC (0.43) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20601783 | 0.86 | RORC (0.43) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL22871302 | 0.85 | MAPT (0.42) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20601680 | 0.84 | MAPT (0.38) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20601634 | 0.82 | MAPT (0.40) | MAPTLMNASMN1; SMN2TP53NR1I2 | |
| SCHEMBL31586280 | 0.81 | MAPT (0.40) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20602219 | 0.81 | MAPT (0.40) | MAPTLMNAALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL20601907 | 0.74 | MAPT (0.45) | MAPTLMNAALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4056557-B1 | BENZAZEPINE DERIVATIVES USEFUL AS MEDICAMENTS | OTSUKA PHARMA CO LTD (JP) | 2023-11-22 | — | — | EP | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-11673878-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-06-13 | — | — | US | disclosed |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-03-18 | — | — | US | disclosed |
| US-10889570-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| US-10889570-B2 | Benzazepine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| EP-3645513-A1 | BENZAZEPINE DERIVATIVES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2020-05-06 | — | — | EP | disclosed |
| CN-110891939-A | Benzazepine derivatives | 大塚制药株式会社 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019004421-A1 | BENZAZEPINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078976-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | MAPT 3910/4885LMNA 1192/4885ALDH1A1 716/4885 |
| US-20230265073-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | MAPT 3910/4885LMNA 1192/4885ALDH1A1 716/4885 |
| US-11673878-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | MAPT 3910/4885LMNA 1192/4885ALDH1A1 716/4885 |
| US-20250051310-A1 | BENZAZEPINE DERIVATIVES | AVPR2, AVPR1A, AVPR1B | MAPT 3362/4885LMNA 782/4885ALDH1A1 628/4885 |
| US-10889570-B2 | Benzazepine derivatives | AVPR2, AVPR1A, AVPR1B | MAPT 3910/4885LMNA 1192/4885ALDH1A1 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.